Unpicking the combination lock for mutant BRAF and RAS melanomas

Bissan Al-Lazikani, Paul Workman

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Large-scale, unbiased combinatorial drug screening has been used to identify effective genotypeselective therapeutic combinations that show promising activity in preclinical models of mutant BRAF and RAS melanoma that are resistant to the clinical BRAF inhibitor vemurafenib.

Original languageEnglish (US)
Pages (from-to)13-19
Number of pages7
JournalCancer discovery
Volume3
Issue number1
DOIs
StatePublished - Jan 2013
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Unpicking the combination lock for mutant BRAF and RAS melanomas'. Together they form a unique fingerprint.

Cite this